论文信息 - Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. - 字舞流文

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.

P. Carroll | E. Small | Peter R. Carroll | E. J. Small

[1] H. Scher,et al. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2] M Mazumdar,et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] H. Scher,et al. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.

[4] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.

[5] G. Kennealey,et al. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. , 1991, The Urologic clinics of North America.

[6] E. Crawford,et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. , 1993, The Journal of urology.